Navigation Links
BELLUS HEALTH reports results for first quarter of fiscal 2008
Date:5/5/2008

-----------------

8,383 16,322

General and administrative 3,314 3,460

Reimbursable costs 22 128

Stock-based compensation 1,035 923

Depreciation, amortization and patent cost

write-off 336 347

-------------------------------------------------------------------------

13,090 21,180

-------------------------------------------------------------------------

Loss before undernoted items (12,863) (20,679)

Interest income 498 613

Interest and bank charges (29) (81)

Accretion expense (1,207) (1,001)

Change in fair value of embedded derivatives 42 -

Write-down of third party asset-backed

commercial paper (375) -

Foreign exchange gain 754 108

Other income 278 242

Share of loss in a company subject to

significant influence - (327)

Non-controlling interest - 109

-------------------------------------------------------------------------

Net loss ($12,902) ($21,016)

-------------------------------------------------------------------------

-------------------------------------------------------------------------

Net loss per share:

Basic and diluted ($
'/>"/>

SOURCE BELLUS Health Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17

Related medicine news :

1. At Annual and Special Meeting of Shareholders - Neurochem to officially adopt new name - BELLUS Health - And to provide update on programs including first new natural health product, VIVIMIND(TM)
2. Penn study finds pro-death proteins required to regulate healthy immune function
3. UCLA researchers identify markers that may predict diabetes in still-healthy people
4. Air pollution linked to cardiovascular risk indices in healthy young adults
5. More proof needed of safety and quality of electronic personal health records
6. Health care incentive model offers collaborative approach
7. Loneliness is bad for your health
8. Mailman School of Public Health study examines link between racial discrimination and substance use
9. Green Tea May Brew Up Healthier Skin
10. For Health Info, Women Often Turn to the Web
11. Record Number of Americans Lack Health Insurance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/7/2009)...ion (Nasdaq: PODD ), the leader in patch pump te...stem, today announced the company will participate...nce. Management is scheduled to present an overvie...009 at The Westin St. Francis in San Francisco, CA...l information concerning the Company, its operatio...
(Date:1/7/2009)...Myers, Inc.,(NYSE: RBN ) today reported diluted ...cal first quarter ended November 30, 2008, as comp...First quarter 2009 sales increased 3% over the,pri...decreased 5% to $185,million. Excluding the impac...tion, organic sales increased 6% and organic order...
(Date:1/7/2009)...he troubles of those born at 39 weeks, , ,...g an elective repeat C-section should wait until t...ave the baby, if there are no medical issues with ...ng just two weeks earlier doubles the risk that th...ng, infection and low blood sugar, according to th...
(Date:1/7/2009)...Patients Unable to Pay Out-of-Pocket Costs, 33 Per...ERs , , SACRAMENTO, Calif., Jan. 7 The econom...tic impact on California,s community hospitals, ac...California Hospital Association (CHA). , , The r...ember 2008 among hospital chief financial officers...
Breaking Medicine News(10 mins):Health News:Robbins & Myers Announces First Quarter 2009 Results 2Health News:Robbins & Myers Announces First Quarter 2009 Results 3Health News:Robbins & Myers Announces First Quarter 2009 Results 4Health News:Robbins & Myers Announces First Quarter 2009 Results 5Health News:Robbins & Myers Announces First Quarter 2009 Results 6Health News:Robbins & Myers Announces First Quarter 2009 Results 7Health News:Robbins & Myers Announces First Quarter 2009 Results 8Health News:Robbins & Myers Announces First Quarter 2009 Results 9Health News:Early Elective C-Sections Produce Complications 2Health News:Early Elective C-Sections Produce Complications 3Health News:Economic Downturn Takes Toll on California Hospitals 2
...othing but a cosmetic nuisance. But sometimes pigm...start dividing abnormally to form a deadly form of...icans born this year will be diagnosed with melano.... Scientists know that 30 percent of all melanomas...
...o mouse chow dramatically reduced spread of aggres... compound in pill form could be used to treat huma...October 1 issue of the journal Cancer Research. Th...rsity of Arizona, is the first to show that the sy...
...nchester Been honored with a prized award for rese...ions who suffer from chronic or acute back pain wo...Best Materials Student annually at the Science, En...ar Awards has been bagged by Racheal Ambury. <...
...has come under criticism from consumer watchdog, C...irls//, preying on their fears about their bodies ...e been screened during the high-rating Australian ...de 13- to 17-year-olds and have reportedly driven ...
Other Medicine News:Health News:Why Don’t All Moles Progress to Melanoma 2Health News:Why Don’t All Moles Progress to Melanoma 3Health News:Super Chow, Laced With Semi-Synthetic Vitamin E, Inhibited Spread of Cancer 2Health News:Super Chow, Laced With Semi-Synthetic Vitamin E, Inhibited Spread of Cancer 3Health News:Obesity Drug Advertisements Misleading Teens 2
(Date:1/6/2009)... , PARIS, France, January 6 /PRNewswire-Fir...nt to Extend the Collaboration Until,December 201...ration to Include Antibody,Discovery in Ophthalmo...nts to ExonHit if Allergan,Sublicenses to a Third... ALEHT) today announced a reinforcement,of its ex...
(Date:1/5/2009)... , BETHESDA, Md., Jan. 5 /PRNewswire-FirstC...armaceutical company developing novel, proprietary...tion and autoimmune diseases,provides an outlook..., Micromet intends to provide an update on it...ing events: , -- April 12 to 16, 2009: Upda...
(Date:1/3/2009)... , , , , , ROSEMONT, Ill., ...ce imaging (MRI) is a growing technology providing...ed in the evaluation of back pain according to an ...f the American Academy of Orthopaedic Surgeons ( h... the next several years, additional technical deve...
(Date:12/29/2008)... , BETHESDA, Md., Dec. 29 /PRNewswire-USNewswir...in Human Research Protection was announced today b...of the Health Improvement Institute. , , The w... Texas M.D. Anderson Cancer Center -- for its b...am." This program provides for 1) enhanced human ...
Breaking Medicine Technology:ExonHit Therapeutics Expands Strategic Collaboration With Allergan 2ExonHit Therapeutics Expands Strategic Collaboration With Allergan 3ExonHit Therapeutics Expands Strategic Collaboration With Allergan 4Micromet Key Events for 2009 2Micromet Key Events for 2009 3Micromet Key Events for 2009 4Micromet Key Events for 2009 5MRI Emerges As Vital Resource in Treatment of Back Pain 2MRI Emerges As Vital Resource in Treatment of Back Pain 32008 Human Research Protection Award Recipients Announced 2Actavis Receives Approval of Generic Wellbutrin XL 28R 29 300mg in the U S 25526 1Actavis Receives Approval of Generic Wellbutrin XL 28R 29 300mg in the U S 25526 2Frost 26 Sullivan Recognizes Waters Corporation for Its Pioneering High Customer Value Analytical Instrumentation Product SYNAPT HDMS 25522 1Frost 26 Sullivan Recognizes Waters Corporation for Its Pioneering High Customer Value Analytical Instrumentation Product SYNAPT HDMS 25522 2Frost 26 Sullivan Recognizes Waters Corporation for Its Pioneering High Customer Value Analytical Instrumentation Product SYNAPT HDMS 25522 3Frost 26 Sullivan Recognizes Waters Corporation for Its Pioneering High Customer Value Analytical Instrumentation Product SYNAPT HDMS 25522 4Fish cancer gene linked to pigment pattern that attracts mates 4514 1Fish cancer gene linked to pigment pattern that attracts mates 4514 22007 hurricane forecasts took blow from winds and Saharan dry dusty air 4510 12007 hurricane forecasts took blow from winds and Saharan dry dusty air 4510 22007 hurricane forecasts took blow from winds and Saharan dry dusty air 4510 3
...s., April 11, 2007 /PRNewswire-FirstCall/ --,Advan...m two,additional Phase III clinical trials of feru...erapeutic that are being,presented today at approx...ney Foundation,s Spring Clinical Meeting in Orland...estor section on the,company,s web site at <a targ...
...tion at EASL on April 13, 2007, 2007, SAN DIEGO, a...all/ -- Anadys Pharmaceuticals, Inc. and LG Life,S...dy showing that,ANA380 (LB80380) retains potency a...s (HBV) which are resistant to lamivudine,adefovi...ntation at,the 42nd Annual Meeting of the European...
Other Medicine Technology:Advanced Magnetics Announces Positive Results from Two Additional,Phase III Studies of Ferumoxytol as an Intravenous Iron Replacement,Therapeutic 2Advanced Magnetics Announces Positive Results from Two Additional,Phase III Studies of Ferumoxytol as an Intravenous Iron Replacement,Therapeutic 3Advanced Magnetics Announces Positive Results from Two Additional,Phase III Studies of Ferumoxytol as an Intravenous Iron Replacement,Therapeutic 4Advanced Magnetics Announces Positive Results from Two Additional,Phase III Studies of Ferumoxytol as an Intravenous Iron Replacement,Therapeutic 5Advanced Magnetics Announces Positive Results from Two Additional,Phase III Studies of Ferumoxytol as an Intravenous Iron Replacement,Therapeutic 6Advanced Magnetics Announces Positive Results from Two Additional,Phase III Studies of Ferumoxytol as an Intravenous Iron Replacement,Therapeutic 7Advanced Magnetics Announces Positive Results from Two Additional,Phase III Studies of Ferumoxytol as an Intravenous Iron Replacement,Therapeutic 8ANA380 Exhibits Activity In Vitro Against Multiple Clinically,Relevant Hepatitis B Virus Mutants 2ANA380 Exhibits Activity In Vitro Against Multiple Clinically,Relevant Hepatitis B Virus Mutants 3ANA380 Exhibits Activity In Vitro Against Multiple Clinically,Relevant Hepatitis B Virus Mutants 4ANA380 Exhibits Activity In Vitro Against Multiple Clinically,Relevant Hepatitis B Virus Mutants 5ANA380 Exhibits Activity In Vitro Against Multiple Clinically,Relevant Hepatitis B Virus Mutants 6
Excellent multi purpose agarose Nuclease-free, Gel point (1.5%): 36 1.5 C, EEO: 0.05-0.13 Gel strength (1%): > 1200 g/cm 2 .
This agarose provides superior resolution of small PCR fragments and primers at lower concentrations than standard agaroses. A 3% gel clearly resolves a 10 bp ladder, and a 4% gel approaches the reso
The PK TP System utilizes fixed chicken erythrocytes sensitized with components of the pathogenic T. pallidum (Nichols Strain) to perform a qualitative screening of Treponema pallidum in human serum
...00 Automated Microplate System, the PK CMV-PA Syst... for the detection of cytomegalovirus. Relative se...ared to EIA measures 99.8% and 99.3% respectively....ides excellent lot-to-lot consistency and eliminat...
Medicine Products: